ALC vs BAX vs HSIC vs HOLX vs IDXX

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Alcon Inc. (ALC) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IDEXX Laboratories, Inc. wins at 2. 68x versus Henry Schein, Inc. 's 4. 20x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus BAX's -41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus Baxter International Inc. 's 1. 38β — meaning BAX is approximately 205% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Alcon Inc. (ALC) carries a lower debt/equity ratio of 24% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -8. 5% for Baxter International Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -2. 7% for BAX. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IDEXX Laboratories, Inc. (IDXX) is the more undervalued stock at a PEG of 2. 68x versus Henry Schein, Inc. 's 4. 20x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 4x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 28. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALC: 35. 5% to $86. 52.

In this comparison, BAX (3.

9% yield), ALC (0. 5% yield) pay a dividend. HSIC, HOLX, IDXX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alcon Inc.

(ALC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 68), 0. 5% yield). Both have compounded well over 10 years (ALC: +11. 4%, IDXX: +542. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALC is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock; HSIC is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; IDXX is a mid-cap quality compounder stock. ALC, BAX pay a dividend while HSIC, HOLX, IDXX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.